Silverberg D S, Iaina A, Reisin E, Rotzak R, Eliahou H E
Br Med J. 1977 Mar 19;1(6063):752-3. doi: 10.1136/bmj.1.6063.752.
In a patient with longstanding severe uraemic pruritus who was undergoing chronic haemodialysis cholestyramine caused the pruritus to disappear completely within a few days. A four-week randomised controlled double-blind study was therefore performed in 10 other patients with uraemic pruritus who were on chronic haemodialysis. The pruritus improved considerably in four of the five treated patients, whereas only one of those treated with placebo experienced relief. The patient who had no relief while on cholestyramine showed a considerable improvement when the dose subsequently doubled. One of the five patients receiving cholestyramine experienced mild and easily reversible constipation, and another suffered nausea. Neither of these complications prevented the patients from continuing treatment. Cholestyramine seems to be useful in treating uraemic pruritus, although it is not known how it acts.
对于一名长期接受慢性血液透析且患有严重尿毒症瘙痒症的患者，消胆胺在数天内使其瘙痒症完全消失。因此，对另外10名接受慢性血液透析的尿毒症瘙痒症患者进行了一项为期四周的随机对照双盲研究。在接受治疗的5名患者中，有4名的瘙痒症有显著改善，而接受安慰剂治疗的患者中只有1名症状得到缓解。服用消胆胺时未缓解的患者在随后剂量加倍后有显著改善。接受消胆胺治疗的5名患者中有1名出现轻度且易于逆转的便秘，另1名出现恶心。这些并发症均未妨碍患者继续治疗。消胆胺似乎对治疗尿毒症瘙痒症有用，尽管其作用机制尚不清楚。
